Session Synopsis: The impact of precision medicine in oncology is undeniable. Precision diagnosis and treatment of cancer at the molecular level has profound implications on the outcome, but requires physician awareness, understanding, and adoption to deliver successful personalized treatment for cancer patients. This session will share the challenges to create a process for organizational and physician engagement while they incorporate precision oncology into practice.
Session Chair Profile
M.D., Chief Medical Officer, Foundation Medicine
Dr. Miller was appointed to serve as our Chief Medical Officer on July 31, 2013. He joined Foundation Medicine in October 2011 and served as our Senior Vice President, Clinical Development between then and July 2013. Dr. Miller previously served as an attending physician at Memorial Sloan-Kettering Cancer Center between July 1991 and October 2011. His work in clinical and translational research in lung cancer culminated in observations and collaborative efforts critical to identification of EGFR sensitizing and resistance mutations. He is considered a world’s expert in lung cancer and clinical trial design and interpretation. Dr. Miller has authored and co-authored numerous abstracts, reviews, and peer-reviewed articles, which have appeared in such journals as Proceedings of the National Academy of Science USA, Cancer Research, Clinical Cancer Research and the Journal of Clinical Oncology. Dr. Miller, a National Merit Scholar, received a BA in mathematics at the University of Pennsylvania, where he was honored as a Benjamin Franklin Scholar, and an MD at the University of Medicine and Dentistry of New Jersey in Newark. He completed an internship and residency, and then served as Chief Medical Resident in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, and subsequently a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center.
M.D., ITOR Medical Director, Greenville Health System
Dr. Edenfield earned his medical degree from the University of Miami, Florida. He completed his internship, residency and fellowship at Walter Reed Army Medical Center in Washington, DC, where he received the Bailey K. Ashford Research Medal. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He served as Chief of Oncology at Womack Army Medical Center in North Carolina. He is a diplomat of the boards of internal medicine, medical oncology, and hematology. He is also board certified by the American Association of Hospice and Palliative Care Medicine in palliative care. Dr. Edenfield has published his works in a number of leading scientific journals. Currently Dr. Edenfield serves as Medical Director of ITOR, Chair of the Division of Oncology at the GHS Cancer Institute, and holds the appointment of Clinical Associate Professor in Hematology/Oncology Division of Internal Medicine, USC School of Medicine.
M.D., Ph.D., Director, Comprehensive Cancer Center and Chairman, Department of Cancer Biology, Wake Forest Baptist Health
Dr. Pasche is a physician scientist and board-certified oncologist. He received M.D. degrees from the Karolinska Institute in Stockholm, Sweden and the University of Lausanne, Switzerland. He received his Ph.D. in coagulation research from the Karolinska Institute and was a postdoctoral fellow at the Brigham and Women Hospital, Harvard Medical School. He completed his internship and residency in Internal Medicine at the New York Hospital, Cornell Medical Center and his fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center. He is Director of the Wake Forest Baptist Comprehensive Cancer Center and Chair of the Department of Cancer Biology. He has developed a novel mouse model of Tgfbr1 haploinsufficiency (Cancer Res 2009, 69:678), which led to the discovery that Tgfbr1 signaling is a potent modifier of colorectal cancer (Science 2008, 321:1361), promotes the development of precancerous lesions in mice (Cancer Res 2009, 69:9169), plays a dual role in pancreatic cancer (J Natl Cancer Inst 2014, 106:1), and promotes fibrosis and immune evasion in the pancreatic tumor microenvironment (Cancer Res 2016, 76:2525). In the past decade, he has tested the new hypothesis that cancer growth may be blocked by low and safe levels of radiofrequency (RF) electromagnetic fields (EMF), which are amplitude modulated (AM) at very specific frequencies identified in patients with a diagnosis of cancer (J Exp Clin Cancer Res 2009, 28:51). His research team has generated robust clinical (Br J Cancer 2011,105:640) and in vitro (Br J Cancer 2012, 106:307) evidence that AM RF EMF blocks the growth of hepatocellular carcinoma. He has served on multiple study sections for NCI, ACS, AACR, DOD and the Komen Foundation. He received the Ohio State University Human Cancer Genetics Program Commemorative Medal. He is an elected member of the American Society for Clinical Investigation (ASCI) and the American Clinical and Climatological Association (ACCA).